AVAlessandro Vindigni

Alessandro Vindigni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Vindigni has a total of 207 co-authors. Here are the top co-authors by number of shared publications:

  • Jessica Jackson

    Division of Oncology, Washington University, St. Louis, USA

    12 shared publications
  • Alice Meroni

    Department of Gynecology, University of Zurich and University Hospital of Zurich, Schlieren, Switzerland

    8 shared publications
  • Annabel Quinet

    Division of Oncology, Department of Medicine, Washington University in St. Louis , St. Louis , MO 63110 , USA

    7 shared publications
  • Alice Meroni

    Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri 63110, USA

    6 shared publications
  • Emily Cybulla

    Division of Oncology, Department of Medicine, Washington University in St. Louis , St. Louis , MO 63110 , USA

    5 shared publications
  • Matthew Wood

    Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, USA

    5 shared publications

Latest Publications

  • Open Access

    TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity

    by Sumedha Agashe, Nidhi Athreya, William Jacobs, Christopher T. Letson, Vladislav O. Sviderskiy, Celia D. Rouault, Yixuan Xie, Carolina Brás-Costa, Emily Zahn, Mary Claire Kendall, et al.

    Somatic mutations in the de novo methyltransferase DNMT3A and cytosine demethylase TET2 are common in age-related clonal hematopoiesis and hematopoietic neoplasms. TET2 mutations, unlike DNMT3A mutations, increase sensitivity to PARP inhibitors (PARPi). We find that TET2 loss, but not DNMT3A loss, alters DNA replication fork progression upon treatment with PARPi Olaparib, resulting in longer DNA replication tracts and increased DNA breaks. This reveals a new link between abnormal fork elongation and PARPi sensitivity in TET2-deficient cells. The elongated forks of TET2-deficient cells contain PRIMPOL-dependent single-stranded (ss)-DNA gaps. This phenotype is dependent on the catalytic activity of TET2 and is mitigated by TET1/3 depletion. Furthermore, TET2 loss causes an imbalance in cytosine methylation and an increase in 5hmU modifications. These modifications are processed by SMUG1, creating abasic sites, detectable via a modified DNA fiber method. A CRISPR screen identified the base excision repair nuclease APE1 as linked to increased PARPi sensitivity in TET2-deficient cells. We propose that abasic sites, skipped by PRIMPOL repriming, lead to ssDNA gaps that are converted into DNA breaks by APE1, increasing PARPi toxicity. Finally, we identify TET2 mutations as an unrecognized predictor of PARPi response in bone marrow samples from patients with myeloid malignancies.

  • Open Access

    The BRCA1-A complex restricts replication fork reversal-dependent DNA repair in ATM deficient cells

    by Arindam Datta, Jessica Jackson, Yaroslav I. Morozov, Jinghan Qiu, Alessandro Vindigni, Roger A. Greenberg

    Ataxia Telangiectasia Mutated (ATM) kinase deficiency results in cancer susceptibility and drug hypersensitivity. Deficiency in either the BRCA1 interacting A complex or XRCC4/Ligase 4 confers resistance to Topoisomerase I or PARP1 inhibitors in ATM-deficient cells. This suggests that BRCA1-A directs toxicity to fork-damaging agents in ATM mutated cells via illegitimate end-joining. Here, we show that ATM inhibition triggers combined SUMO and ubiquitin mediated BRCA1-A damaged fork recognition to restrict end-resection and cause Topoisomerase I inhibitor hypersensitivity. BRCA1-A deficient cells display elevated chromatin accessibility and nuclease activity at damaged forks, coupled with restored resection and drug resistance. Electron microscopy evidence demonstrates that ATM inhibition prevents replication fork reversal, which is restored by BRCA1-A loss to generate substrates for end resection. These findings reveal that BRCA1-A enforces a restrictive chromatin state to suppress the genesis of resection substrates, implicating fork reversal as a key determinant of chemotherapy response in ATM deficient cells.


  • Open Access

    FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability

    by Celeste Giansanti, Jack C. Schultz, Jessica Jackson, Alessandro Vindigni, David Cortez

    Targeting replication-associated DNA repair mechanisms, including the control of ADP-ribosylation by PARP1/2 and PARG, is a powerful therapeutic approach for cancer. However, the mechanisms by which PARG inhibition impacts DNA replication remain unclear. Here, we combine isolation of proteins on nascent DNA (iPOND) with quantitative proteomics and functional assays to investigate replication fork dynamics upon acute PARG inhibition. We find that FET family proteins (FUS, EWS, and TAF15) are recruited to replication forks in a PAR-dependent manner, forming condensates that slow fork progression and promote fork reversal. FET proteins control fork dynamics in response to some, but not all, replication stresses. FUS inactivation leads to unrestrained fork progression via RECQ1 and PRIMPOL, increased single-stranded DNA gaps, genome instability, and synthetic lethality with BRCA1 deficiency. These findings reveal that FET protein assemblies modulate replication stress responses, influencing genome stability and the cellular response to cancer therapeutics targeting PARylation pathways.


  • Open Access

    Condensin and topoisomerases cooperate to relieve topological stress at stalled replication forks

    by Mégane Da Mota, Axel Delamarre, Antoine Barthe, Jessica Jackson, Nail Bouzalmad, Alba Torán-Vilarrubias, Yea-Lih Lin, Cyril Ribeyre, Alessandro Vindigni, Philippe Pasero, et al.

    Resolving complex topological structures at replication forks is essential for faithful DNA replication, yet the underlying mechanisms remain poorly understood. Evidence from diverse eukaryotes suggests that condensin – best known for driving chromosome condensation in mitosis – may also operate during S phase to alleviate torsional stress in cooperation with topoisomerases. Here, we show in budding yeast and human cells that condensin binds stressed replication forks, where it cooperates with topoisomerases I and II to promote nascent DNA resection and restart replication. Our data indicate that condensin acts together with topoisomerase I at reversed forks to convert positive supercoils into topological DNA structures that are relaxed by topoisomerase II, enabling fork restart. These findings reveal an evolutionarily conserved role for condensin in resolving topological constraints at arrested forks, reminiscent of its function in chromosome segregation, and suggest that this activity helps prevent the formation of toxic chromosome structures during fork arrest and reversal.


  • Open Access

    Synthetic lethality of decitabine plus ATR inhibition for TP53 -mutated AML

    by Jeremy T. Baeten, Sumedha Agashe, Imene Tabet, Jack T. Wooldridge, Amber Carter, Jamie N. Butler, Christopher A. Miller, Nicole Helton, Annabel Quinet, Kimberly B. Johansson, et al.

    TP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely complete and nearly all patients relapse. Molecular determinants of response to HMAs in TP53-MN are poorly understood. Here, we show that decitabine induces replicative stress with decreased replication fork progression, induction of single-strand DNA breaks, and activation of the ataxia telangiectasia mutated–Rad3-related (ATR) pathway. Resolution of decitabine-induced replication stress is impaired in TP53-mutated acute myeloid leukemia (AML) cells, representing a potential therapeutic vulnerability. Indeed, the combination of decitabine and ATR inhibition (ATRi) induces synthetic lethality that is selective for TP53-AML and due, in part, to induction of mitotic catastrophe. Interestingly, this synergistic lethality was not observed with azacitidine or treatment with GSK3685032, a potent DNA methyltransferase 1 inhibitor, both of which produce a comparable level of global hypomethylation to decitabine. Treatment with decitabine and an ATR inhibitor reduces leukemia burden and prolongs survival in in vivo mouse models of TP53-mutated AML. Collectively, these findings show that TP53 loss generates a selective vulnerability to decitabine-induced replication stress, with the combination of ATRi and decitabine showing promise as a new therapeutic approach for TP53-MN.


  • Open Access

    FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability

    by Celeste Giansanti, Jack C. Schultz, Jessica Jackson, Alessandro Vindigni, David Cortez

    Targeting replication-associated DNA repair mechanisms, including those regulated by PARP1/2 and PARG control of ADP-ribosylation is a powerful cancer therapeutic approach. However, the mechanisms by which PARG inhibition impacts DNA replication remain unclear. Here we combined isolation of proteins on nascent DNA (iPOND) with quantitative proteomics and functional assays to investigate replication fork dynamics upon acute PARG inhibition. We found that FET family proteins (FUS, EWS, and TAF15) are recruited to replication forks in a PAR-dependent manner, forming condensates that slow fork progression and promote fork reversal. FET proteins control fork dynamics in response to some, but not all, replication stresses. FUS inactivation leads to unrestrained fork progression via RECQ1 and PRIMPOL, increased single-stranded DNA gaps, genome instability, and synthetic lethality with BRCA1 deficiency. These findings reveal that FET protein condensates modulate replication stress responses, influencing genome stability and the cellular response to cancer therapeutics targeting PARylation pathways.

  • The replication stress response: Mechanisms and functions

    by Alberto Ciccia, Alessandro Vindigni

  • Open Access

    MRN–CtIP, EXO1, and DNA2–WRN/BLM act bidirectionally to process DNA gaps in PARPi-treated cells without strand cleavage

    by Isabelle M. Seppa, Ilaria Ceppi, Mithila Tennakoon, Giordano Reginato, Jessica Jackson, Celia D. Rouault, Sumedha Agashe, Vladislav O. Sviderskiy, Mangsi Limbu, Erica Lantelme, et al.

    Single-stranded DNA (ssDNA) gaps impact genome stability and PARP inhibitor (PARPi) sensitivity, especially in BRCA1/2-deficient tumors. Using single-molecule DNA fiber analysis, electron microscopy, and biochemical methods, we found that MRN, CtIP, EXO1, and DNA2–WRN/BLM resect ssDNA gaps through a mechanism different from their actions at DNA ends. MRN resects ssDNA gaps in the 3′-to-5′ direction using its pCtIP-stimulated exonuclease activity. Unlike at DNA ends, MRN does not use its endonucleolytic activity to cleave the 5′-terminated strand flanking the gap or the ssDNA. EXO1 and DNA2–WRN/BLM specifically resect the 5′ end of the gap independent of MRN–CtIP. This resection process alters ssDNA gap repair kinetics in BRCA1-proficient and -deficient cells. In BRCA1-deficient cells treated with PARPis, excessive resection results in larger ssDNA gaps, hindering their repair and leading to DNA breaks in subsequent cell cycle stages due to ssDNA gaps colliding with DNA replication forks. These findings broaden our understanding of the role of human nucleases in DNA metabolism and have significant implications for defining the mechanisms driving PARPi sensitivity in BRCA-deficient tumors.


  • Open Access

    Genetic buffering mechanisms in SNF2-family translocases

    by Sumedha Agashe, Alessandro Vindigni


  • Open Access

    Nucleolytic processing of abasic sites underlies PARP inhibitor hypersensitivity in ALC1-deficient BRCA mutant cancer cells

    by Natasha Ramakrishnan, Tyler M. Weaver, Lindsey N. Aubuchon, Ayda Woldegerima, Taylor Just, Kevin Song, Alessandro Vindigni, Bret D. Freudenthal, Priyanka Verma

    Clinical success with poly (ADP-ribose) polymerase inhibitors (PARPi) is impeded by inevitable resistance and associated cytotoxicity. Depletion of Amplified in Liver Cancer 1 (ALC1), a chromatin-remodeling enzyme, can overcome these limitations by hypersensitizing BReast CAncer genes 1/2 (BRCA1/2) mutant cells to PARPi. Here, we demonstrate that PARPi hypersensitivity upon ALC1 loss is reliant on its role in promoting the repair of chromatin buried abasic sites. We show that ALC1 enhances the ability of the abasic site processing enzyme, Apurinic/Apyrimidinic endonuclease 1 (APE1) to cleave nucleosome-occluded abasic sites. However, unrepaired abasic sites in ALC1-deficient cells are readily accessed by APE1 at the nucleosome-free replication forks. APE1 cleavage leads to fork breakage and trapping of PARP1/2 upon PARPi treatment, resulting in hypersensitivity. Collectively, our studies reveal how cells overcome the chromatin barrier to repair abasic lesions and uncover cleavage of abasic sites as a mechanism to overcome limitations of PARPi.